Neurogen Corporation

(NASDAQ:NRGN)

0.10

+0.01 (6.56%)

1:22ET Delayed

Open
0.09
High
0.10
Low
0.08
Vol.
122.27K
Mkt Cap
6.50M
52Wk High
4.13
52Wk Low
0.06
Avg. Vol.
464.10K
P/E (Trailing)
Beta
1.02
Short %
1.60%
Div. Yield

Company Profile

Neurogen Corporation

35 Northeast Industrial Road

Branford, CT 06405

United States - Map

Phone: (203) 488-8201

Fax: (203) 481-8683

Website: www.neurogen.com

State of incorporation: Delaware

CEO: Stephen R. Davis, J.D., CPA

Employees: 149

Sector: Healthcare

Industry Group: Drugs

Industry: Drug Manufacturers - Other

Dev/mfr prods for neurological disorders

A drug discovery & development company focusing on new small molecule drugs to improve the lives of patients suffering from disorders with unmet medical need including insomnia, obesity, pain, Parkinson's disease, Restless Legs Syndrom

Recent opinions on NRGN

No recent Opinions for NRGN

No members own NRGN

Member sentiment: Neutral